DE60119347D1 - Verwendung von chimäres il6-il6r in huntingtonskrankheit - Google Patents

Verwendung von chimäres il6-il6r in huntingtonskrankheit

Info

Publication number
DE60119347D1
DE60119347D1 DE60119347T DE60119347T DE60119347D1 DE 60119347 D1 DE60119347 D1 DE 60119347D1 DE 60119347 T DE60119347 T DE 60119347T DE 60119347 T DE60119347 T DE 60119347T DE 60119347 D1 DE60119347 D1 DE 60119347D1
Authority
DE
Germany
Prior art keywords
il6r
chimeric
huntington disease
huntington
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60119347T
Other languages
English (en)
Other versions
DE60119347T2 (de
Inventor
Nicole Deglon
Patrick Aebischer
Jean-Charles Bensadoun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ares Trading SA
Original Assignee
Ares Trading SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading SA filed Critical Ares Trading SA
Application granted granted Critical
Publication of DE60119347D1 publication Critical patent/DE60119347D1/de
Publication of DE60119347T2 publication Critical patent/DE60119347T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
DE60119347T 2000-09-14 2001-09-10 Verwendung von chimäres il6-il6r in huntingtonskrankheit Expired - Lifetime DE60119347T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00120045 2000-09-14
EP00120045 2000-09-14
PCT/EP2001/010442 WO2002022149A1 (en) 2000-09-14 2001-09-10 Use of il-6r/il-6 chimera in huntington's disease

Publications (2)

Publication Number Publication Date
DE60119347D1 true DE60119347D1 (de) 2006-06-08
DE60119347T2 DE60119347T2 (de) 2007-02-22

Family

ID=8169836

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60119347T Expired - Lifetime DE60119347T2 (de) 2000-09-14 2001-09-10 Verwendung von chimäres il6-il6r in huntingtonskrankheit

Country Status (13)

Country Link
US (3) US20040057928A1 (de)
EP (1) EP1317273B1 (de)
JP (1) JP5030364B2 (de)
AT (1) ATE324906T1 (de)
AU (2) AU2001291849B2 (de)
CA (1) CA2419954C (de)
CY (1) CY1105116T1 (de)
DE (1) DE60119347T2 (de)
DK (1) DK1317273T3 (de)
ES (1) ES2262680T3 (de)
IL (2) IL154777A0 (de)
PT (1) PT1317273E (de)
WO (1) WO2002022149A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL147412A0 (en) * 2001-12-31 2002-08-14 Yeda Res & Dev The use of il6r/il6 chimera in nerve cell regeneration
WO2004037281A1 (en) * 2002-10-24 2004-05-06 The University Of British Columbia Methods for neuroprotection
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
CA2527847C (en) * 2003-06-12 2015-09-29 Yeda Research & Development Co. Ltd Enhancement of oligodendrocyte differentiation
WO2005035564A2 (en) 2003-10-10 2005-04-21 Xencor, Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
ME03079B (de) 2012-06-08 2019-01-20 Alkermes Pharma Ireland Ltd Durch zirkuläre permutaton modifizierte liganden als agonisten und antagonisten

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
IL99803A (en) * 1991-10-20 1997-02-18 Yeda Res & Dev Pharmaceutical compositions comprising interleukin-6 for the treatment of chronic lymphocytic leukemia and B-cell lymphomas
US5792900A (en) * 1991-10-21 1998-08-11 The Trustees Of The University Of Pennsylvania Compositions and methods for producing and using homogenous neuronal cell transplants
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
DK1895010T3 (da) * 1997-12-22 2011-11-21 Oxford Biomedica Ltd Vektorer baseret på virus for infektiøs hesteanæmi (eiav)
JP4859153B2 (ja) * 1999-02-25 2012-01-25 東ソー株式会社 新規神経系細胞分化促進剤
IL130586A0 (en) * 1999-06-21 2000-06-01 Yeda Res & Dev IL6RIL6 chimera for the treatment of demyelinating diseases

Also Published As

Publication number Publication date
IL154777A0 (en) 2003-10-31
EP1317273A1 (de) 2003-06-11
ATE324906T1 (de) 2006-06-15
CA2419954A1 (en) 2002-03-21
US20100166703A1 (en) 2010-07-01
US8329654B2 (en) 2012-12-11
IL154777A (en) 2010-11-30
DK1317273T3 (da) 2006-09-04
US20040057928A1 (en) 2004-03-25
DE60119347T2 (de) 2007-02-22
JP2004508409A (ja) 2004-03-18
ES2262680T3 (es) 2006-12-01
US20070172454A1 (en) 2007-07-26
AU9184901A (en) 2002-03-26
WO2002022149A1 (en) 2002-03-21
CY1105116T1 (el) 2009-11-04
EP1317273B1 (de) 2006-05-03
AU2001291849B2 (en) 2005-11-24
JP5030364B2 (ja) 2012-09-19
PT1317273E (pt) 2006-09-29
CA2419954C (en) 2012-01-03

Similar Documents

Publication Publication Date Title
CY1107248T1 (el) Συντηγμενες πρωτεϊνες
HK1077518A1 (en) Peptides that modulate nerve growth factor (ngf) activity, their compositions and use
DOP2002000429A (es) Imidazotriazinas
CY1111912T1 (el) Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
DE69427650D1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
RS51737B (sr) Korišćenje inhibitora il-18
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
BRPI0414215A (pt) tienopirazóis
BRPI0409359A (pt) análogos quiméricos de somatostatina-dopamina
ATE363531T1 (de) Claudin polypeptide
DE60228878D1 (de) Proteine mit il-6 inhibitorischer wirkung
CY1105116T1 (el) Χρηση των il-6r/il-6 χιμαιρων στη νοσο του huntington
SE0102147D0 (sv) New methods
DK1228097T3 (da) Antimikrobiel aktivitet af den förste kationiske humane lactoferrin-klynge
BR0012291A (pt) Fenoxifluorpirimidinas
RS11104A (en) Combined preparations,containing 1,4- benzothiepine-1,1- dioxide derivatives and other active substances, and the use thereof
DK1331940T3 (da) Anvendelse af det lange pentraxin PTX3 til behandling af sygdomme forårsaget af ændret aktivering af vækstfaktoren FGF-2
DK1185293T3 (da) IL6RIL6-kimær til behandling af neurodegenerative sygdomme
DE60125232D1 (de) Kleines säurelösliches sporenprotein und seine verwendungen
CY1106363T1 (el) Χρηση του ενepγοποιημενου παραγοντα πηξης vii για την αγωγη των επαγομενων απο θρομβολυτικη θepαπεια μειζονων αιμορραγιων
RS51316B (sr) Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli
DK1012286T3 (da) Allelvariant af humant STAT3
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition